Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole

被引:30
作者
Gawronska-Szklarz, Barbara [1 ]
Siuda, Andrzej [2 ]
Kurzawski, Mateusz [1 ]
Bielicki, Dariusz [3 ]
Marlicz, Wojciech [3 ]
Drozdzik, Marek [1 ]
机构
[1] Pomeranian Med Univ, Dept Pharmacol, PL-70111 Szczecin, Poland
[2] Reg Hosp, Clin Dept Internal Dis, PL-66530 Drezdenko, Poland
[3] Pomeranian Med Univ, Dept Gastroenterol, PL-70111 Szczecin, Poland
关键词
CYP2C19; MDR1; Interleukin-1; beta; Genetic polymorphism; Peptic ulcer; H; pylori; Pharmacogenetics; PEPTIC-ULCER PATIENTS; C3435T POLYMORPHISM; CURE RATES; SUSCEPTIBILITY; LANSOPRAZOLE; MEPHENYTOIN; METABOLISM; OMEPRAZOLE; CLARITHROMYCIN; RESISTANCE;
D O I
10.1007/s00228-010-0818-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Eradication of H. pylori is an important treatment strategy in peptic ulcer patients. Current regimens of eradication consist of proton pump inhibitor (PPI) and two antibiotics. Effects of PPI may depend on their metabolism, and other factors important for the pathophysiology of peptic ulcer disease. Aim of the present study was to evaluate an association of CYP2C19, MDR1, and IL-1B polymorphisms with the eradication rate of H. pylori in Polish Caucasian patients treated with a triple therapy of pantoprazole, amoxicillin, and metronidazole. A total of 139 peptic ulcer patients, positive for H. pylori infection, were treated with triple therapy (pantoprazole + amoxicillin + metronidazole). Subsequently, the patients were divided into two groups (group 1, success, and group 2, failure of eradication after therapy) and genotyped by the PCR-RFLP method for the presence of CYP2C19 variant alleles (*2, *3, and *17), and MDR1 3435C > T and IL-1B +3954C > T polymorphisms. Pantoprazole serum concentrations were measured using the HPLC method. No significant differences in frequency or distribution of CYP2C19 genotypes were found between the two groups of patients (i.e., with successful H. pylori eradication and treatment failure). However, any carrier of defective CYP2C19*2/*2 genotype was found among patients with treatment failure. Similarly, MDR1 and IL-1B genotypes were found to be significantly associated with the success or failure of H. pylori eradication. Univariate and multivariate analysis of the genotypes did not reveal any significant association between the genotypes and H. pylori eradication. Pantoprazole concentrations differed significantly, and were the highest in patients with defective allele CYP2C19*2 carriers and lowest in hyperactive genotype homozygotes CYP2C19*17/*17. The results suggest that the CYP2C19 genotype contrary to MDR1 and IL-1B genotypes may have an impact on the efficacy of H. pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole.
引用
收藏
页码:681 / 687
页数:7
相关论文
共 31 条
  • [1] SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS
    ANDERSSON, T
    REGARDH, CG
    DAHLPUUSTINEN, ML
    BERTILSSON, L
    [J]. THERAPEUTIC DRUG MONITORING, 1990, 12 (04) : 415 - 416
  • [2] Barone J A, 2001, Manag Care, V10, P11
  • [3] The status of antimicrobial resistance of Helicobacter pylori in eastern Europe
    Boyanova, L
    Mentis, A
    Gubina, M
    Rozynek, E
    Gosciniak, G
    Kalenic, S
    Göral, V
    Kupcinskas, L
    Kantarçeken, B
    Aydin, A
    Archimandritis, A
    Dzierzanowska, D
    Vcev, A
    Ivanova, K
    Marina, M
    Mitov, I
    Petrov, P
    Özden, A
    Popova, M
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (07) : 388 - 396
  • [4] Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
    Cascorbi, I
    Gerloff, T
    Johne, A
    Meisel, C
    Hoffmeyer, S
    Schwab, M
    Schaeffeler, E
    Eichelbaum, M
    Brinkmann, U
    Roots, I
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 169 - 174
  • [5] Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer
    Chakravorty, M
    Ghosh, A
    Choudhury, A
    Santra, A
    Hembrum, J
    Roychoudhury, S
    [J]. HUMAN MUTATION, 2006, 27 (05) : 411 - 419
  • [6] The importance of interleukin 1β in Helicobacter pylori associated disease
    El-Omar, EM
    [J]. GUT, 2001, 48 (06) : 743 - 747
  • [7] Interleukin-1 polymorphisms associated with increased risk of gastric cancer
    El-Omar, EM
    Carrington, M
    Chow, WH
    McColl, KEL
    Bream, JH
    Young, HA
    Herrera, J
    Lissowska, J
    Yuan, CC
    Rothman, N
    Lanyon, G
    Martin, M
    Fraumeni, JF
    Rabkin, CS
    [J]. NATURE, 2000, 404 (6776) : 398 - 402
  • [8] Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP2C19 genotypes and 23S rRNA genotypes of H-pylori
    Furuta, T.
    Sugimoto, M.
    Shirai, N.
    Matsushita, F.
    Nakajima, H.
    Kumagai, J.
    Senoo, K.
    Kodaira, C.
    Nishino, M.
    Yamade, M.
    Ikuma, M.
    Watanabe, H.
    Umemura, K.
    Ishizaki, T.
    Hishida, A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (05) : 693 - 703
  • [9] Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
    Furuta, T
    Shirai, N
    Takashima, M
    Xiao, F
    Hanai, H
    Sugimura, H
    Ohashi, K
    Ishizaki, T
    Kaneko, E
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 158 - 168
  • [10] Polymorphism of Interleukin-1β Affects the Eradication Rates of Helicobacter pylori by Triple Therapy
    Furuta, Takahisa
    Shirai, Naohito
    Xiao, Fang
    El-omar, Emad M.
    Rabkin, Charles S.
    Sugimura, Haruhiko
    Ishizaki, Takashi
    Ohashi, Kyoichi
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (01) : 22 - 30